MannKind Corporation Q3 2025 Earnings Recap

MNKD Q3 2025 November 6, 2025

MannKind Corporation reported a record revenue of $82 million in Q3 2025, driven by strong product performance and the recent acquisition of scPharmaceuticals, positioning the company for significant growth ahead.

Earnings Per Share Beat

$0.03 vs $0.01 est.

+200.0% surprise

Revenue Miss

82130000 vs 99850000 est.

-17.7% surprise

Market Reaction

1-Day -5.94%

5-Day -13.37%

30-Day -10.4%

Key Takeaways

Q3 2025 revenue reached $82 million, marking a record for the company, with Tyvaso DPI contributing $59 million in royalties and manufacturing revenue.
The supplemental BLA for Afrezza was accepted for review, with a PDUFA date set for Q2 2026, highlighting potential pediatric market entry.
FUROSCIX revenue grew by 95% year-to-date compared to 2024, with significant adoption, including over 27,000 doses dispensed in Q3, anticipated to reflect in Q4 results post-acquisition.
The acquisition of scPharmaceuticals enhances MannKind's commercial scale and accelerates growth into cardiorenal medicine, targeting a substantial market opportunity in heart failure and chronic kidney disease.
Afrezza prescription growth continued, with a 31% increase in new prescriptions year-over-year, despite a shift in focus towards type 1 diabetes.

This summary was generated by AI from the official earnings call transcript and is provided for informational purposes only. It does not constitute financial advice. For the complete transcript and financial data, visit MNKD on AllInvestView.